Quark Publishes Data Linking Proprietary Target to Pulmonary Injury, Emphysema
May 20, 2010
Quark Publishes Data Linking Proprietary Target to Pulmonary Injury, Emphysema
The new data in pulmonary injury and emphysema provide "support for additional clinical applications of this drug, such as treatment of acute and chronic lung injury," according to a company official.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quark Begins Dosing Second Patient Subgroup in Phase I Study of Ocular Neuroprotection siRNA Drug
October 21, 2010 / Gene Silencing News - Quark Sees Nitto Denko Deal as 'Harbinger' of Future Partnerships
August 5, 2010 / Gene Silencing News - Quark, Nitto Denko Collaborate on RNAi Drugs for Fibrotic Disease
July 15, 2010 / Gene Silencing News - Quark Delayed Graft Function Drug Gets European Orphan Drug Status
June 17, 2010 / Gene Silencing News - Quark Delayed Graft Function Drug Safe in Phase I
May 6, 2010 / Gene Silencing News